The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2015

Filed:

Jul. 17, 2012
Applicants:

Jane Hirsh, Wellesley, MA (US);

Alexander M. Klibanov, Newton, MA (US);

Timothy M. Swager, Newton, MA (US);

Stephen L. Buchwald, Newton, MA (US);

Whe Yong Lo, Canton, MA (US);

Alison Fleming, Marshfield, MA (US);

Roman V. Rariy, Allston, MA (US);

Inventors:

Jane Hirsh, Wellesley, MA (US);

Alexander M. Klibanov, Newton, MA (US);

Timothy M. Swager, Newton, MA (US);

Stephen L. Buchwald, Newton, MA (US);

Whe Yong Lo, Canton, MA (US);

Alison Fleming, Marshfield, MA (US);

Roman V. Rariy, Allston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 9/42 (2006.01); A61K 31/20 (2006.01); A61K 31/485 (2006.01); A61K 9/16 (2006.01); A61K 47/12 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1617 (2013.01); A61K 47/12 (2013.01); A61K 9/4858 (2013.01); A61K 31/20 (2013.01); A61K 9/145 (2013.01); A61K 9/5052 (2013.01); A61K 9/5084 (2013.01); A61K 31/485 (2013.01);
Abstract

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.


Find Patent Forward Citations

Loading…